The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant Clinical Trial

Official title:

Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04023214
• Other study ID #: STH15983
• Status: Completed
• Start date: July 25, 2011
• Est. completion date: December 31, 2018

Study information

• Verified date: July 2019
• Source: Sheffield Teaching Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This pilot study will compare endothelial function in patients with ADPKD with matched healthy volunteers and normotensive chronic kidney disease stage 1 & 2 patients. Patients will undergo a single assessment of endothelial function and measurement of plasma and urine levels of biomarkers of endothelial function.

Description:

Following recruitment we will record the following baseline demographics; age, gender, smoking status, body mass index, medical history.

Participants will undergo a noninvasive vascular assessment, venepuncture and will provide a urine sample.This will be done during a single visit to the CRF.

Noninvasive vascular assessment will consist of:

1. Peripheral Arterial Tonometry This will be measured using the EndoPAT system (Itamar Medical)

Endothelial shear stress flow stimulus will be provided by inflation of a blood pressure cuff around the upper non-dominant arm to suprasystolic pressure (but <300mmHg) for 5 minutes. Following release of the cuff the resulting digital microcirculation vasodilatory response to ischaemic hyperaemia, quantified as the pulse wave amplitude, will be monitored over 5 minutes. The peak pulse wave amplitude measured at 90-150s post cuff deflation relative to baseline will be indexed to the changes in the opposite arm to give the reactive hyperaemia index. This measure of endothelial function constitutes the outcome measure.

2. Blood Pressure Assessment Brachial artery blood pressure will be measured in the left arm in the supine position using an automated device (Dinamap) and in accordance with the clinical research facility SOP.

3. Blood samples and urine samples

Samples for plasma will be centrifuged and stored at -80C. Biochemical analysis will be performed by the laboratory of the STH NHS Trust for standard tests and by validated assays for non-routine markers (as detailed below) in the Academic Nephrology Unit.

Participants will be asked to collect a 24h urine sample from the day before the study visit and to provide a spot urine sample on the day. This will be analysed at the laboratory of the STH NHS Trust.

Biochemical Analysis

Serum samples will be analyzed for Full blood count, Urea, Electrolytes, Glucose, Insulin, Lipid Profile, Homocysteine, (Hs) CRP and Creatinine Levels.

Serum and plasma will also be stored for future analysis of relevant biomarkers of endothelial function or nitric oxide metabolism as indicated by preliminary results.

Urine samples will be analysed initially for protein creatinine ratio (PCR). The rest will be frozen for future analysis of urinary biomarkers of endothelial function or nitric oxide metabolism.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 31, 2018
• Est. primary completion date: December 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Age >18yrs, <50yrs

• Able to understand spoken/written English sufficiently to give informed consent and to take part in clinical assessment

• Clinical diagnosis of ADPKD

• eGFR >60ml/min/1.73m2

Exclusion Criteria:

• No history of cardiovascular disease or hypertension

• Not diabetic

• Not smoking

• Not breastfeeding

• Not pregnant

• Not taking any regular medication (except oral contraceptives)

• No musculoskeletal conditions contraindicating inflation of a blood pressure cuff to suprasystolic pressures around the forearm (as part of EndoPAT measurements)

• Not morbidly obese: BMI<35 (May contribute to endothelial dysfunction)

• eGFR <60ml/min/1.73m2

Related Conditions & MeSH terms

• Kidney Diseases
• Polycystic Kidney Diseases
• Polycystic Kidney, Autosomal Dominant

Intervention

Diagnostic Test:
• Peripheral (digital) arterial tonometry
This will be measured using the EndoPAT system (Itamar Medical)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust	University of Sheffield

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reactive hyperemia index (RHI)	EndoPAT values (Endoscore)	Baseline
Secondary	Systolic and diastolic Blood pressure	mm Hg	Baseline
Secondary	Proteinuria	Protein creatinine ratio	Baseline